NASDAQ:RARE - Ultragenyx Pharmaceutical Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $143.94
Forecasted Upside: 50.74 %
Number of Analysts: 14
Breakdown:
0 Sell Ratings
4 Hold Ratings
10 Buy Ratings
0 Strong Buy Ratings

^$95.49 As of 06/21/2021 06:08 PM ET

▲ +0.57 (0.60%)

1 month | 3 months | 12 months

Get New Ultragenyx Pharmaceutical Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for RARE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RARE

^$143.94

▲ +50.74% Upside Potential

This price target is based on 14 analysts offering 12 month price targets for Ultragenyx Pharmaceutical in the last 3 months. The average price target is $143.94, with a high forecast of $186.00 and a low forecast of $88.00. The average price target represents a 50.74% upside from the last price of $95.49.

Current Consensus is Buy

The current consensus among 14 polled investment analysts is to buy stock in Ultragenyx Pharmaceutical. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
7 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

12/29/2019

0 strong buy ratings
7 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

3/28/2020

0 strong buy ratings
11 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

6/26/2020

0 strong buy ratings
11 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

9/24/2020

0 strong buy ratings
11 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

12/23/2020

0 strong buy ratings
10 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

3/23/2021

0 strong buy ratings
11 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

5/22/2021

0 strong buy ratings
10 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

6/21/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
5/9/2021	SVB Leerink	Initiated Coverage	Buy	$178.00	High
5/6/2021	Citigroup	Upgrade	Neutral ➝ Buy	$160.00 ➝ $151.00	High
5/6/2021	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Upgrade	Neutral ➝ Buy	$160.00 ➝ $151.00	High
5/5/2021	Evercore ISI	Upgrade	In-Line ➝ Outperform	$144.00	High
5/5/2021	Morgan Stanley	Lower Price Target	Overweight	$170.00 ➝ $156.00	Low
4/19/2021	Morgan Stanley	Lower Price Target	Overweight	$175.00 ➝ $170.00	Medium
3/1/2021	Stifel Nicolaus	Initiated Coverage	Buy	$179.00	High
2/16/2021	SVB Leerink	Boost Price Target	Outperform	$115.00 ➝ $178.00	Low
2/12/2021	Wedbush	Boost Price Target	Neutral	$113.00 ➝ $130.00	Low
2/12/2021	Piper Sandler	Boost Price Target	Overweight	$165.00 ➝ $170.00	Low
2/12/2021	Barclays	Boost Price Target	Overweight	$176.00 ➝ $186.00	Low
2/12/2021	JPMorgan Chase & Co.	Downgrade	Overweight ➝ Neutral	$165.00	Low
1/25/2021	Credit Suisse Group	Boost Price Target	Neutral	$64.00 ➝ $99.00	High
1/11/2021	Robert W. Baird	Boost Price Target	Outperform	$110.00 ➝ $165.00	Medium
1/11/2021	Barclays	Boost Price Target	Overweight	$121.00 ➝ $176.00	High
12/7/2020	Wedbush	Downgrade	Outperform ➝ Neutral	$105.00 ➝ $110.00	Medium
11/24/2020	Evercore ISI	Reiterated Rating	In-Line	$110.00	High
11/12/2020	Bank of America	Downgrade	Buy ➝ Neutral	$104.00 ➝ $126.00	High
10/29/2020	Canaccord Genuity	Boost Price Target	Buy	$92.00 ➝ $105.00	High
10/28/2020	Truist	Boost Price Target		$88.00 ➝ $110.00	High
10/28/2020	Wedbush	Boost Price Target	Outperform	$97.00 ➝ $105.00	Low
10/28/2020	Morgan Stanley	Boost Price Target	Overweight	$89.00 ➝ $91.00	Low
10/28/2020	Barclays	Boost Price Target	Overweight	$99.00 ➝ $121.00	Medium
10/28/2020	SVB Leerink	Boost Price Target	Outperform	$110.00 ➝ $115.00	Medium
10/27/2020	Piper Sandler	Boost Price Target	Overweight	$83.00 ➝ $108.00	Medium
10/15/2020	Bank of America	Boost Price Target	Buy	$93.00 ➝ $107.00	Medium
10/13/2020	Morgan Stanley	Boost Price Target	Overweight	$87.00 ➝ $89.00	Medium
8/26/2020	Canaccord Genuity	Boost Price Target	Buy	$91.00 ➝ $92.00	High
7/31/2020	Credit Suisse Group	Reiterated Rating	Hold	$64.00	Low
7/31/2020	Morgan Stanley	Lower Price Target	Overweight	$88.00 ➝ $87.00	High
7/31/2020	Barclays	Boost Price Target	Overweight	$87.00 ➝ $99.00	Low
7/28/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy	$84.00	High
7/15/2020	Morgan Stanley	Boost Price Target	Overweight	$83.00 ➝ $88.00	Low
7/2/2020	Canaccord Genuity	Boost Price Target	Buy	$85.00 ➝ $91.00	Medium
7/1/2020	SunTrust Banks	Boost Price Target		$82.00 ➝ $88.00	Medium
7/1/2020	Credit Suisse Group	Boost Price Target	Neutral	$60.00 ➝ $64.00	High
7/1/2020	JPMorgan Chase & Co.	Boost Price Target	Overweight	$76.00 ➝ $84.00	High
7/1/2020	Wedbush	Boost Price Target	Hold ➝ Outperform	$83.00 ➝ $91.00	High
7/1/2020	Morgan Stanley	Boost Price Target	Overweight	$79.00 ➝ $83.00	High
7/1/2020	Robert W. Baird	Boost Price Target	Outperform	$75.00 ➝ $90.00	High
6/30/2020	Piper Sandler	Boost Price Target	Overweight	$70.00 ➝ $83.00	High
6/19/2020	SunTrust Banks	Boost Price Target	Buy	$80.00 ➝ $82.00	High
6/19/2020	Wedbush	Boost Price Target	Outperform	$73.00 ➝ $83.00	High
6/19/2020	Canaccord Genuity	Boost Price Target	Buy	$75.00 ➝ $85.00	High
5/18/2020	Stifel Nicolaus	Boost Price Target	Positive ➝ Buy	$70.00 ➝ $82.00	High
5/8/2020	Citigroup	Boost Price Target	Neutral	$53.00 ➝ $66.00	Low
4/1/2020	Robert W. Baird	Reiterated Rating	Buy	$75.00	High
2/18/2020	Evercore ISI	Reiterated Rating	Buy		Low
2/16/2020	JPMorgan Chase & Co.	Reiterated Rating	Buy	$76.00	Low
2/14/2020	Wedbush	Boost Price Target	Outperform	$71.00 ➝ $75.00	High
2/14/2020	Cowen	Reiterated Rating	Buy	$75.00	High
1/17/2020	Morgan Stanley	Boost Price Target	Overweight	$73.00 ➝ $77.00	Low
1/10/2020	SunTrust Banks	Reiterated Rating	Buy	$75.00 ➝ $80.00	High
1/2/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		High
12/18/2019	Piper Jaffray Companies	Reiterated Rating	Buy	$70.00	High
12/18/2019	Cowen	Reiterated Rating	Buy	$59.00	High
12/17/2019	Morgan Stanley	Lower Price Target	Overweight	$76.00 ➝ $73.00	Medium
11/6/2019	Morgan Stanley	Lower Price Target	Overweight	$79.00 ➝ $76.00	High
11/6/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$75.00	High
11/5/2019	Cowen	Reiterated Rating	Buy	$62.00	High
9/4/2019	Piper Jaffray Companies	Set Price Target	Buy	$75.00	Low
9/4/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy		Low
9/4/2019	SVB Leerink	Reiterated Rating	Outperform ➝ Positive	$80.00 ➝ $85.00	High
8/15/2019	Wedbush	Reiterated Rating	Buy	$75.00	High
8/15/2019	Cowen	Reiterated Rating	Buy		High
8/5/2019	JPMorgan Chase & Co.	Reiterated Rating	Buy	$75.00	Medium
8/4/2019	Barclays	Reiterated Rating	Buy	$87.00	Medium
8/2/2019	Morgan Stanley	Lower Price Target	Overweight	$83.00 ➝ $79.00	High
8/2/2019	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$75.00	High
6/17/2019	Morgan Stanley	Set Price Target	Buy	$83.00	Low
5/9/2019	Barclays	Reiterated Rating	Buy		Low
5/7/2019	Wedbush	Reiterated Rating	Outperform	$88.00 ➝ $77.00	High
3/27/2019	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$68.00 ➝ $83.00	Medium
2/26/2019	Cowen	Reiterated Rating	Buy	$69.00	High
2/22/2019	Raymond James	Reiterated Rating	Outperform ➝ Outperform	$80.00	Low
2/21/2019	Citigroup	Boost Price Target	Neutral ➝ Neutral	$54.00 ➝ $62.00	High
2/20/2019	Credit Suisse Group	Reiterated Rating	Hold	$59.00	High
1/23/2019	SunTrust Banks	Boost Price Target	Buy	$71.00	High
1/7/2019	Wedbush	Reiterated Rating	Outperform	$88.00	Medium
1/7/2019	Cowen	Reiterated Rating	Buy		Medium
1/4/2019	Credit Suisse Group	Set Price Target	Hold	$59.00	Medium
1/2/2019	Raymond James	Downgrade	Outperform ➝ Market Perform		Medium
11/15/2018	Credit Suisse Group	Set Price Target	Hold	$59.00	High
11/14/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
11/8/2018	Citigroup	Upgrade	Sell ➝ Neutral	$46.00 ➝ $54.00	N/A
11/7/2018	Canaccord Genuity	Lower Price Target	Buy	$90.00 ➝ $75.00	Low
11/6/2018	Raymond James	Boost Price Target	Outperform ➝ Buy	$53.00 ➝ $57.00	Medium
10/29/2018	Wedbush	Lower Price Target	Outperform ➝ Outperform	$90.00 ➝ $88.00	High
10/29/2018	Citigroup	Lower Price Target	Sell ➝ Sell	$49.00 ➝ $46.00	High
10/29/2018	Morgan Stanley	Set Price Target	Hold	$92.00 ➝ $70.00	High
10/29/2018	Credit Suisse Group	Lower Price Target	Neutral ➝ Hold	$78.00 ➝ $59.00	High
10/29/2018	SunTrust Banks	Lower Price Target	Buy ➝ Buy	$83.00 ➝ $54.00	Medium
10/27/2018	JPMorgan Chase & Co.	Set Price Target	Buy	$68.00	Medium
10/26/2018	Raymond James	Set Price Target	Buy	$70.00	Low
10/26/2018	Piper Jaffray Companies	Lower Price Target	Overweight	$70.00	High
10/7/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy	$86.00	Low
9/11/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$72.00 ➝ $94.00	Low
9/10/2018	Morgan Stanley	Reiterated Rating	Equal ➝ Equal Weight	$92.00	Low
9/2/2018	JMP Securities	Reiterated Rating	Buy	$94.00	Medium
8/30/2018	Wedbush	Boost Price Target	Outperform ➝ Outperform	$80.00 ➝ $90.00	Medium
8/29/2018	JPMorgan Chase & Co.	Reiterated Rating	Buy		Medium
8/20/2018	SunTrust Banks	Boost Price Target	Buy ➝ Positive	$83.00	Low
8/6/2018	Wedbush	Boost Price Target	Outperform ➝ Outperform	$71.00 ➝ $80.00	High
8/3/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$80.00 ➝ $90.00	High
8/3/2018	Robert W. Baird	Reiterated Rating	Buy	$95.00	High
8/3/2018	Barclays	Reiterated Rating	Overweight ➝ Overweight	$74.00 ➝ $92.00	High
8/3/2018	Piper Jaffray Companies	Boost Price Target	Overweight	$85.00	High
7/17/2018	SVB Leerink	Boost Price Target	Outperform ➝ Outperform	$68.00 ➝ $95.00	Low
6/21/2018	Credit Suisse Group	Downgrade	Outperform ➝ Neutral	$67.00 ➝ $80.00	High
5/11/2018	Barclays	Upgrade	Equal Weight ➝ Overweight	$62.00 ➝ $74.00	High
5/10/2018	The Goldman Sachs Group	Initiated Coverage	Neutral ➝ Neutral	$63.00	Medium
4/18/2018	Cowen	Reiterated Rating	Buy		Medium
4/18/2018	Stifel Nicolaus	Boost Price Target	Buy ➝ Buy	$74.00 ➝ $77.00	High
4/18/2018	Wedbush	Reiterated Rating	Outperform ➝ Positive	$64.00 ➝ $71.00	High
4/18/2018	JMP Securities	Boost Price Target	Outperform	$70.00 ➝ $74.00	High
4/18/2018	SunTrust Banks	Upgrade	Hold ➝ Buy	$41.67 ➝ $55.00	Low
4/17/2018	Bank of America	Boost Price Target		$61.00 ➝ $72.00	Low
3/22/2018	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Overweight	$67.00	Medium
2/23/2018	Robert W. Baird	Reiterated Rating	Buy	$70.00	Medium
2/21/2018	Bank of America	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $61.00	High
2/21/2018	Morgan Stanley	Reiterated Rating	Equal Weight ➝ Equal Weight	$57.00 ➝ $60.00	High
2/21/2018	JPMorgan Chase & Co.	Reiterated Rating	Market Outperform ➝ Overweight	$68.00 ➝ $66.00	High
2/21/2018	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$85.00 ➝ $74.00	High
1/22/2018	Evercore ISI	Upgrade	In-Line ➝ Outperform		High
1/17/2018	Credit Suisse Group	Initiated Coverage	Outperform ➝ Outperform	$67.00	Low
12/15/2017	Raymond James	Reiterated Rating	Buy		Low
12/5/2017	Raymond James	Reiterated Rating	Buy		Medium
12/5/2017	Canaccord Genuity	Set Price Target	Buy	$80.00	Medium
12/5/2017	Barclays	Boost Price Target	Equal Weight ➝ Equal Weight	$60.00 ➝ $62.00	High
12/4/2017	Jefferies Financial Group	Upgrade	Hold ➝ Buy	$58.00 ➝ $72.00	High
11/16/2017	Canaccord Genuity	Set Price Target	Buy	$83.00 ➝ $80.00	N/A
11/15/2017	Cowen	Reiterated Rating	Buy		N/A
11/5/2017	JPMorgan Chase & Co.	Reiterated Rating	Buy	$76.00	N/A
11/3/2017	Robert W. Baird	Lower Price Target	Outperform	$85.00 ➝ $80.00	N/A
10/6/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$69.00 ➝ $71.00	N/A
9/19/2017	Robert W. Baird	Reiterated Rating	Buy		Low
9/14/2017	Wedbush	Upgrade	Neutral ➝ Outperform	$62.00	High
9/12/2017	Canaccord Genuity	Reiterated Rating	Buy		Low
9/6/2017	Barclays	Initiated Coverage	Equal Weight	$60.00	High
8/23/2017	Jefferies Financial Group	Set Price Target	Hold	$62.00	Low
8/23/2017	JPMorgan Chase & Co.	Set Price Target	Buy	$87.00 ➝ $76.00	Low
8/23/2017	JMP Securities	Lower Price Target	Market Outperform	$90.00 ➝ $80.00	Low
8/23/2017	Morgan Stanley	Reiterated Rating	Equal Weight	$80.00 ➝ $69.00	High
8/23/2017	Stifel Nicolaus	Reiterated Rating	Buy	$95.00 ➝ $85.00	High
8/23/2017	SVB Leerink	Reiterated Rating	Outperform	$89.00 ➝ $83.00	High
8/23/2017	Cowen	Reiterated Rating	Outperform		High
8/23/2017	SunTrust Banks	Downgrade	Buy ➝ Hold	$105.00 ➝ $55.00	High
8/22/2017	Canaccord Genuity	Reiterated Rating	Buy	$98.00 ➝ $83.00	High
8/16/2017	Evercore ISI	Initiated Coverage	In ➝ In-Line	$63.00	High
8/8/2017	HC Wainwright	Reiterated Rating	Neutral ➝ Neutral	$72.00 ➝ $75.00	Low
7/28/2017	Canaccord Genuity	Set Price Target	Buy	$98.00	Low
7/27/2017	Sanford C. Bernstein	Initiated Coverage	Market Perform	$72.00	High
7/14/2017	Jefferies Financial Group	Reiterated Rating	Hold	$68.00	High
6/30/2017	Stifel Nicolaus	Reiterated Rating	Buy	$111.00	Low
6/29/2017	Cowen	Reiterated Rating	Outperform		Low
5/8/2017	Canaccord Genuity	Reiterated Rating	Buy		Low
5/8/2017	Morgan Stanley	Lower Price Target	Equal Weight	$84.00 ➝ $79.00	Low
5/8/2017	Jefferies Financial Group	Boost Price Target	Hold	$66.00 ➝ $68.00	Low
4/19/2017	Robert W. Baird	Reiterated Rating	Outperform	$90.00	Medium
4/19/2017	Cowen	Reiterated Rating	Outperform		Medium
4/19/2017	SunTrust Banks	Boost Price Target	Buy	$100.00 ➝ $105.00	Medium
4/19/2017	Canaccord Genuity	Reiterated Rating	Buy	$100.00	High
4/19/2017	Wedbush	Downgrade	Outperform ➝ Neutral	$80.00 ➝ $75.00	High
4/19/2017	HC Wainwright	Downgrade	Buy ➝ Neutral	$88.00 ➝ $72.00	High
4/6/2017	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$109.00 ➝ $66.00	High
3/23/2017	HC Wainwright	Reiterated Rating	Buy		High
3/23/2017	Cowen	Reiterated Rating	Buy		High
3/23/2017	Canaccord Genuity	Reiterated Rating	Buy	$100.00	Medium
3/23/2017	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Neutral		High
3/23/2017	Wedbush	Lower Price Target	Buy	$88.00 ➝ $80.00	High
3/22/2017	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$96.00 ➝ $70.00	High
2/17/2017	Cowen	Reiterated Rating	Buy		N/A
2/17/2017	Wedbush	Initiated Coverage	Outperform	$88.00	N/A
2/17/2017	Jefferies Financial Group	Reiterated Rating	Buy	$109.00	N/A
11/30/2016	Citigroup	Downgrade	Neutral ➝ Sell		N/A
11/30/2016	Wedbush	Reiterated Rating	Outperform	$92.00	N/A
11/30/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$96.00	N/A
11/14/2016	Jefferies Financial Group	Set Price Target	Buy	$109.00	N/A
11/14/2016	SVB Leerink	Reiterated Rating	Outperform	$94.00 ➝ $90.00	N/A
11/14/2016	Citigroup	Downgrade	Neutral ➝ Sell	$66.00 ➝ $64.00	N/A
11/11/2016	Canaccord Genuity	Set Price Target	Buy	$103.00	N/A
11/9/2016	JPMorgan Chase & Co.	Reiterated Rating	Buy	$106.00	N/A
11/8/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$79.00	N/A
11/8/2016	Wedbush	Reiterated Rating	Outperform	$92.00	N/A
10/21/2016	Canaccord Genuity	Set Price Target	Buy	$120.00	N/A
9/25/2016	HC Wainwright	Reiterated Rating	Buy	$102.00 ➝ $109.00	N/A
9/20/2016	Canaccord Genuity	Set Price Target	Buy	$120.00	N/A
9/20/2016	SVB Leerink	Reiterated Rating	Outperform	$85.00 ➝ $94.00	N/A
9/19/2016	Wedbush	Reiterated Rating	Outperform	$92.00	N/A
9/18/2016	Jefferies Financial Group	Set Price Target	Buy	$109.00	N/A
9/14/2016	Credit Suisse Group	Reiterated Rating	Buy	$101.00	N/A
9/12/2016	Jefferies Financial Group	Set Price Target	Buy	$109.00	N/A
8/25/2016	SVB Leerink	Reiterated Rating	Buy	$86.00	N/A
8/9/2016	Cowen	Reiterated Rating	Buy		N/A
8/9/2016	Piper Jaffray Companies	Set Price Target	Buy	$70.00 ➝ $82.00	N/A
8/9/2016	Credit Suisse Group	Reiterated Rating	Buy	$101.00	N/A
8/9/2016	Wedbush	Reiterated Rating	Outperform	$92.00	N/A
8/8/2016	JPMorgan Chase & Co.	Set Price Target	Buy	$110.00	N/A
8/1/2016	Jefferies Financial Group	Set Price Target	Buy	$109.00	N/A
7/18/2016	Robert W. Baird	Reiterated Rating	Outperform	$85.00	N/A
7/17/2016	Jefferies Financial Group	Reiterated Rating	Buy		N/A
7/17/2016	Piper Jaffray Companies	Reiterated Rating	Overweight	$70.00	N/A
7/15/2016	Cowen	Reiterated Rating	Buy		N/A
7/15/2016	SVB Leerink	Reiterated Rating	Buy	$85.00	N/A
7/15/2016	Canaccord Genuity	Reiterated Rating	Buy	$120.00	N/A
7/12/2016	Credit Suisse Group	Reiterated Rating	Buy		N/A
7/7/2016	Piper Jaffray Companies	Initiated Coverage	Overweight	$70.00	N/A
6/28/2016	Wedbush	Reiterated Rating	Outperform	$92.00	N/A
6/28/2016	Bank of America	Initiated Coverage	Buy	$72.00	N/A

(Data available from 6/21/2016 forward)

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; and Dojolvi for treating long-chain fatty acid oxidation disorders. The company is also developing DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.

Today's Range

Now: $95.49

$93.56

$96.77

50 Day Range

MA: $105.14

$92.19

$115.71

52 Week Range

Now: $95.49

$72.43

$179.65

Volume

993,471 shs

Average Volume

465,694 shs

Market Capitalization

$6.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.91

Frequently Asked Questions

What sell-side analysts currently cover shares of Ultragenyx Pharmaceutical?

The following equities research analysts have issued reports on Ultragenyx Pharmaceutical in the last twelve months: Bank of America Co., Barclays PLC, Canaccord Genuity, Citigroup Inc., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, Credit Suisse Group AG, Evercore ISI, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Robert W. Baird, Stifel Nicolaus, SunTrust Banks, Inc., SVB Leerink LLC, TheStreet, Truist, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for RARE.

What is the current price target for Ultragenyx Pharmaceutical?

16 Wall Street analysts have set twelve-month price targets for Ultragenyx Pharmaceutical in the last year. Their average twelve-month price target is $143.94, suggesting a possible upside of 50.5%. Barclays PLC has the highest price target set, predicting RARE will reach $186.00 in the next twelve months. SunTrust Banks, Inc. has the lowest price target set, forecasting a price of $88.00 for Ultragenyx Pharmaceutical in the next year.
View the latest price targets for RARE.

What is the current consensus analyst rating for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical currently has 4 hold ratings and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe RARE will outperform the market and that investors should add to their positions of Ultragenyx Pharmaceutical.
View the latest ratings for RARE.

What other companies compete with Ultragenyx Pharmaceutical?

Other companies that are similar to Ultragenyx Pharmaceutical include MERCK Kommanditgesellschaft auf Aktien, Horizon Therapeutics Public, Alnylam Pharmaceuticals, UCB, Catalent, Viatris, Elanco Animal Health, BioMarin Pharmaceutical, Zai Lab, Grifols, Dr. Reddy's Laboratories, CureVac, Maravai LifeSciences, Ono Pharmaceutical and Teva Pharmaceutical Industries.

How do I contact Ultragenyx Pharmaceutical's investor relations team?

Ultragenyx Pharmaceutical's physical mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company's listed phone number is 415-483-8800 and its investor relations email address is [email protected] The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.